Elaine M. Jagoda, M.S.

Elaine M. Jagoda, M.S.
Staff Scientist
Head, Laboratory of Radiopharmaceutical Development

Elaine Jagoda serves as the lead for the Laboratory of Radiopharmaceutical Development in the Molecular Imaging Program of the National Cancer Institute. She has over 20 years of research experience in the development of PET/SPECT imaging agents in academic (George Washington University, Washington, DC),  pharmaceutical (Bristol-Myers Squibb, Princeton, NJ; Merck Research Laboratories, West Point, PA), and government (PET Dept, Clinical Center; NIBIB, Bethesda, MD) settings.  Her research is focused on pre-clinical development of  novel PET molecular imaging agents for cancer which would work hand in hand with new targeted therapies proving useful not only for patient diagnosis and selection but in monitoring patient responses as well.

Areas of Expertise
PET/SPECT Imaging, Molecular Imaging, Radiopharmaceutical Development, Radioligand Assay Development

Contact Info

Elaine M. Jagoda, M.S.
Center for Cancer Research
National Cancer Institute
Building 10, Room B3B406
Bethesda, MD 20892-1088
Ph: 240-858-3068
Fax: 240-541-4527
ejagoda@mail.nih.gov

Info. to come

Selected Recent Publications

  1. Immuno-PET of the Tumor Endothelial Marker 8.
    Kuo F, Histed S, Xu B, Bhadrasetty V, Szajek LP, Williams MR, Wong K, Wu H, Lane K, Coble V, Vasalatiy O, Griffiths GL, Paik CH, Elbuluk O, Szot C, Chaudhary A, St Croix B, Choyke P, Jagoda EM
    Mol Pharm. 11: 3996-4006, 2014. [ Journal Article ]
  2. Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab.
    Jagoda EM, Lang L, Bhadrasetty V, Histed S, Williams M, Kramer-Marek G, Mena E, Rosenblum L, Marik J, Tinianow JN, Merchant M, Szajek L, Paik C, Cecchi F, Raffensperger K, Jose-Dizon JM, Bottaro DP, Choyke P
    J Nucl Med. 53(10): 1592-1600, 2012. [ Journal Article ]
  3. [76Br]BMK-152, a Nonpeptide Analogue, With High Affinity and Low Nonspecific Binding for the Corticotropin-Releasing Factor Type 1 Receptor.
    Jagoda EM, Lang L, McCullough K, Contoreggi C, Kim BM, Ma Y, Rice KC, Szajek LP, Eckelman WC, Kiesewetter DO
    Synapse. 65(9): 910-918, 2011. [ Journal Article ]
  4. Regional brain uptake of the muscarinic ligand, [18F]FP-TZTP is greatly decreased in M2 receptor knockout mice but not in M1, M2, M3, and M4 receptor knockout mice.
    Jagoda EM, Kiesewetter DO, Shimoji K, Ravasi L,Yamada M, Gomeza J, Wess J, and Eckelman WC
    Neuropharmacology. 44(5): 653-661, 2003. [ Journal Article ]
  5. Imaging the Met Receptor Tyrosine Kinase (Met) and Assessing Tumor Responses to a Met Tyrosine Kinase Inhibitor in Human Xenograft Mouse Models with a [99mTc] (AH-113018) or Cy 5** (AH-112543) Labeled Peptide.
    E.M. Jagoda, S. Bhattacharyya, J. Kalen, L. Riffle, A. Leeder, S. Histed, M. Williams, KJ. Wong, B. Xu, LP. Szajek, O. Elbuluk, F. Cecchi, K. Raffensperger, M. Golla, D. P. Bottaro, and P. Choyke
    Mol Imaging. 14: 499-515, 2015. [ Journal Article ]

Elaine Jagoda serves as the lead for the Laboratory of Radiopharmaceutical Development in the Molecular Imaging Program of the National Cancer Institute.  Ms.Jagoda has over 20 years of research experience in the development of PET/SPECT imaging agents in academic (George Washington University, Washington, DC),  pharmaceutical (Bristol-Myers Squibb, Princeton, NJ; Merck Research Laboratories, West Point, PA), and government (PET Dept, Clinical Center; NIBIB, Bethesda, MD) settings.  My research is focused on pre-clinical development of  novel PET molecular imaging agents for cancer which would work hand in hand with new targeted therapies proving useful not only for patient diagnosis and selection but in monitoring patient responses as well.